Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T20:11:45.580Z.
Consensus retrieved: 2026-10-06T11:50:48.711Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:11:45.580Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cd3ead22764b77a02cf3e742533c366d0c9255af04c84535b20f2b2666bee2a
Forward PE Ratio (N/A) = Dated Quote Price ($1.67) / Consensus Forward EPS ($-0.50)
FORWARD PE RATIO
N/A
Gain Therapeutics, Inc.
Market Cap
$71.23M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $71.23M | N/A |
| Tiziana Life Sciences Ltd (TLSA)vs › | $70.63M | N/A |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.32M | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $69.88M | 50.30 |
| MindWalk Holdings Corp. (HYFT)vs › | $72.83M | N/A |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | N/A |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | N/A |
| iBio, Inc. (IBIO)vs › | $67.52M | N/A |
| Pulmonx Corporation (LUNG)vs › | $75.18M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.67, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.50 | $-0.52 – $-0.48 | 3 | n/m |
| 2027-12-31 | $-0.65 | $-0.77 – $-0.58 | 3 | n/m |
| 2028-12-31 | $-0.68 | $-0.84 – $-0.51 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
